What is CRITERIUM?
CRITERIUM operates as a full-service Clinical Research Organization (CRO), dedicated to optimizing clinical trial solutions for pharmaceutical companies and research institutions. With a legacy spanning over three decades, the company excels in reducing costs and accelerating market approval timelines. Their comprehensive service portfolio includes robust clinical trial management, in-depth retrospective studies, and the deployment of innovative technology solutions. CRITERIUM's therapeutic expertise is broad, encompassing oncology, dermatology, and orthopedics, with a particular emphasis on managing complex cancer trials. Strategic collaborations with leading universities in the USA and Canada further bolster their capabilities in translational research, positioning them as a key player in advancing medical science.
How much funding has CRITERIUM raised?
CRITERIUM has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in CRITERIUM
PPP
Public-Private Partnership
What's next for CRITERIUM?
The substantial late-stage funding context suggests CRITERIUM is poised for significant expansion and strategic initiatives. This capital injection is likely to fuel further development of their technological platforms, enhance their service offerings, and potentially broaden their global reach. The company's focus on complex therapeutic areas and its established university partnerships indicate a strategic direction towards tackling more challenging research projects and solidifying its leadership in the CRO market. Future growth may involve acquisitions or deeper integration of advanced data analytics to further streamline clinical trial processes and deliver enhanced value to clients.
See full CRITERIUM company page
